In cervical cancers, low RIPK3 protein expression in patient biopsies correlated to a reduced response to PolyIC-based adjuvant immunotherapeutic approaches.19 In patients suffering from intestinal bowel disease and presenting with colorectal cancer, loss of RIPK3 expression was detected in neoplastic tissue compared with non-neoplastic and the loss of expression was correlative to a poor prognosis.20 These findings suggest a role for RIPK3 and potentially necroptosis in tumorigenesis, as well as prognosis. Here, RIPK3 is linked to colorectal cancer.